NDUFAB1作为牛脂肪细胞中NEFA诱导的代谢功能障碍的新型调节剂
Jing Zhou1, Tao Tang1, Wenqiang Sun1
1College of Animal Science and Technology, Sichuan Agricultural University, Chengdu 611130, China.
Animals : an open access journal from MDPI
|June 13, 2025
概括
高含量的非化脂肪酸会损害乳牛脂肪细胞的功能,抑制生长并促进脂质的积累. NDUFAB1的激活可以抵消这些影响,为代谢性疾病提供潜在的治疗点.
科学领域:
- 动物科学动物科学
- 代谢生物化学 代谢生物化学
- 细胞生理学 细胞生理学
背景情况:
- 过高的非化脂肪酸 (NEFA) 与乳牛的代谢障碍有关.
- NEFA对脂肪细胞 (脂肪细胞) 功能的确切影响尚未完全理解.
研究的目的:
- 研究高NEFA度对牛脂肪细胞功能的影响.
- 为了确定参与NEFA诱导的脂肪细胞功能障碍的分子调节剂.
- 探索NDUFAB1作为牛代谢疾病的潜在治疗标.
主要方法:
- 对暴露于NEFA的牛脂肪细胞的综合转录和功能分析.
- 评估脂肪细胞的增殖,分化和脂质沉积.
- 研究NDUFAB1在缓解NEFA诱导的细胞功能障碍中的作用.
主要成果:
- 高度的NEFA显著抑制了牛脂肪细胞的增殖和分化 (p < 0.01).
- 暴露于NEFA会促进脂肪细胞内的病态脂质积累.
- NDUFAB1被确定为一种关键的代谢调节剂,可以对抗NEFA诱导的脂肪细胞功能障碍.
- 表明NDUFAB1激活可以减轻过度NEFA的细胞毒性作用.
结论:
- 高水平的NEFA会损害乳牛的关键脂肪细胞功能.
- NDUFAB1对NEFA诱导的细胞损伤起着保护作用.
- 准NDUFAB1是一个有希望的策略,用于管理牛的代谢障碍.
相关概念视频
Overview of Fatty Acid Metabolism
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


